# ATALANTE: Atezolizumab vs Placebo Phase III Study in Late Relapse Ovarian Cancer Treated With Chemotherapy+Bevacizumab

> **NCT02891824** · PHASE3 · COMPLETED · sponsor: **ARCAGY/ GINECO GROUP** · enrollment: 614 (actual)

## Conditions studied

- Ovarian Cancer

## Interventions

- **DRUG:** atezolizumab + avastin + platinum-based chemotherapy
- **DRUG:** placebo + avastin + platinum-based chemotherapy

## Key facts

- **NCT ID:** NCT02891824
- **Lead sponsor:** ARCAGY/ GINECO GROUP
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-09-22
- **Primary completion:** 2021-10-15
- **Final completion:** 2024-02-22
- **Target enrollment:** 614 (ACTUAL)
- **Last updated:** 2025-02-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02891824

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02891824, "ATALANTE: Atezolizumab vs Placebo Phase III Study in Late Relapse Ovarian Cancer Treated With Chemotherapy+Bevacizumab". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02891824. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*